HRP20120230T1 - Triazolopiridini kao inhibitori par1, njihovo dobivanje i upotreba kao medikamenata - Google Patents

Triazolopiridini kao inhibitori par1, njihovo dobivanje i upotreba kao medikamenata Download PDF

Info

Publication number
HRP20120230T1
HRP20120230T1 HR20120230T HRP20120230T HRP20120230T1 HR P20120230 T1 HRP20120230 T1 HR P20120230T1 HR 20120230 T HR20120230 T HR 20120230T HR P20120230 T HRP20120230 T HR P20120230T HR P20120230 T1 HRP20120230 T1 HR P20120230T1
Authority
HR
Croatia
Prior art keywords
alkyl
cycloalkyl
alkylene
triazolo
imino
Prior art date
Application number
HR20120230T
Other languages
English (en)
Croatian (hr)
Inventor
Heinelt Uwe
Wehner Volkmar
Herrmann Matthias
Sch�Nafinger Karl
Steinhagen Henning
Scheiper Bodo
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi filed Critical Sanofi
Publication of HRP20120230T1 publication Critical patent/HRP20120230T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HR20120230T 2008-02-05 2009-01-23 Triazolopiridini kao inhibitori par1, njihovo dobivanje i upotreba kao medikamenata HRP20120230T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08290112 2008-02-05
PCT/EP2009/000406 WO2009097970A1 (de) 2008-02-05 2009-01-23 Triazolopyridazine als par1-inhibitoren, ihre herstellung und verwendung als arzneimittel

Publications (1)

Publication Number Publication Date
HRP20120230T1 true HRP20120230T1 (hr) 2012-04-30

Family

ID=39539711

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20120230T HRP20120230T1 (hr) 2008-02-05 2009-01-23 Triazolopiridini kao inhibitori par1, njihovo dobivanje i upotreba kao medikamenata

Country Status (31)

Country Link
US (2) US8076336B2 (sr)
EP (1) EP2240487B1 (sr)
JP (1) JP5526040B2 (sr)
KR (1) KR20100114514A (sr)
CN (1) CN101981034B (sr)
AR (1) AR070410A1 (sr)
AT (1) ATE537172T1 (sr)
AU (1) AU2009211887B2 (sr)
BR (1) BRPI0907486A2 (sr)
CA (1) CA2713550C (sr)
CL (1) CL2009000236A1 (sr)
CO (1) CO6260083A2 (sr)
CY (1) CY1113228T1 (sr)
DK (1) DK2240487T3 (sr)
ES (1) ES2379447T3 (sr)
HR (1) HRP20120230T1 (sr)
IL (1) IL207205A0 (sr)
MA (1) MA32061B1 (sr)
MX (1) MX2010008490A (sr)
MY (1) MY152040A (sr)
NZ (1) NZ587141A (sr)
PA (1) PA8814801A1 (sr)
PE (1) PE20091455A1 (sr)
PL (1) PL2240487T3 (sr)
PT (1) PT2240487E (sr)
RS (1) RS52264B (sr)
RU (1) RU2499797C2 (sr)
SI (1) SI2240487T1 (sr)
TW (1) TW200946532A (sr)
WO (1) WO2009097970A1 (sr)
ZA (1) ZA201004467B (sr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008036272A1 (en) * 2006-09-18 2008-03-27 Vertex Pharmaceuticals Incorporated HETEROCYCLIC INHIBITORS OF c-MET AND USES THEREOF
BRPI0907487A2 (pt) * 2008-02-05 2015-07-14 Sanofi Aventis Sais de triazólio como inibidores de par1, produção dos mesmos e uso como medicamentos
US8673890B2 (en) 2009-10-29 2014-03-18 Janssen Pharmaceutica Nv 2,3-dihydro-1H-isoindol-1-imine derivatives useful as thrombin PAR-1 receptor antagonist
AR119198A1 (es) * 2019-06-19 2021-12-01 Nmd Pharma As Proceso para la preparación de inhibidores del canal de cloruro cic-1
PL4031552T3 (pl) 2019-09-16 2025-03-17 Takeda Pharmaceutical Company Limited Pochodne azolowo-skondensowanych pirydazyn-3(2h)-onów
CN117304210A (zh) * 2022-06-21 2023-12-29 南京理工大学 二硝胺类四并环高能量密度材料及其合成方法
CN116982626B (zh) * 2023-07-25 2026-01-27 广西田园生化股份有限公司 一种具有二氨基吡咯并喹唑啉骨架的化合物在防治植物病原细菌中的用途
CN119528900B (zh) * 2024-08-08 2026-03-13 河南科技大学 具有抗肝癌活性的甲基噻唑衍生物及其制备方法和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4578464A (en) 1983-11-22 1986-03-25 Merrell Dow Pharmaceuticals Inc. 6-Hydroxyalkylamino-8-methyl-1,2,4-triazolo-[4,3-b]pyridazine and related compounds
WO1996008496A1 (en) * 1994-09-16 1996-03-21 Takeda Chemical Industries, Ltd. Triazolopyridazines process and intermediates for their preparation and their use as medicaments
US6063847A (en) 1997-11-25 2000-05-16 Schering Corporation Thrombin receptor antagonists
US7488742B2 (en) 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
US7476688B2 (en) * 2001-04-19 2009-01-13 Eisai R&D Management Co., Ltd. Cyclic amidine derivatives
EP1391452A4 (en) 2001-05-25 2005-10-26 Mochida Pharm Co Ltd 4-HYDROXPIPERIDIN DERIVATIVE ANALGETIC EFFECT
EP1439178A4 (en) 2001-10-05 2005-11-16 Takeda Pharmaceutical Heterocyclic compounds, oxazole derivatives, process for their preparation and their use
KR100960170B1 (ko) 2001-10-18 2010-05-26 쉐링 코포레이션 트롬빈 수용체 길항제로서의 힘바신 동족체
JP4558331B2 (ja) 2002-04-16 2010-10-06 シェーリング コーポレイション 三環式トロンビンレセプターアンタゴニスト
JP4549970B2 (ja) 2003-02-19 2010-09-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 環状ベンズアミジン誘導体の製造方法
TW200531688A (en) 2004-03-05 2005-10-01 Hoffmann La Roche Novel pentafluorosulfanyl compounds, their manufacture and use as pharmaceutical agents
EP1813282A4 (en) 2004-11-09 2011-03-02 Eisai R&D Man Co Ltd MEANS FOR THE TREATMENT OF ANGIOSPASM IN SUBARACHO-OAL BLOODING WITH THROMBIN RECEPTOR ANTAGONIST AS AN ACTIVE AGENT
HUE030390T2 (en) * 2005-12-21 2017-05-29 Janssen Pharmaceutica Nv Triazolopyridazines as tyrosine kinase modulators
DE102006025318A1 (de) * 2006-05-31 2007-12-06 Bayer Healthcare Ag Dihydro-pyrrolopyridin-, Dihydro-pyrrolopyridazin- und Dihydro-pyrrolopyrimidin-Derivate und ihre Verwendung
DE102006036023A1 (de) * 2006-08-02 2008-02-07 Sanofi-Aventis Imino-imidazo-pyridinderivate mit antithrombotischer Aktivität
SI2242740T1 (sl) 2008-02-05 2013-03-29 Sanofi SF5-derivati kot PAR1 inhibitorji, njihova priprava in uporaba kot zdravila
PL2240179T3 (pl) 2008-02-05 2017-08-31 Sanofi Imidazopirydazyny jako inhibitory PAR1, ich wytwarzanie i zastosowanie jako leku
BRPI0907487A2 (pt) 2008-02-05 2015-07-14 Sanofi Aventis Sais de triazólio como inibidores de par1, produção dos mesmos e uso como medicamentos
WO2009126624A1 (en) 2008-04-11 2009-10-15 Bristol-Myers Squibb Company Triazolo compounds useful as dgat1 inhibitors
US8394823B2 (en) 2008-04-11 2013-03-12 Bristol-Myers Squibb Company Triazolopyridine compounds useful as DGAT1 inhibitors

Also Published As

Publication number Publication date
ATE537172T1 (de) 2011-12-15
BRPI0907486A2 (pt) 2015-07-14
ES2379447T3 (es) 2012-04-26
CL2009000236A1 (es) 2009-06-05
CO6260083A2 (es) 2011-03-22
US20120010203A1 (en) 2012-01-12
ZA201004467B (en) 2011-09-28
KR20100114514A (ko) 2010-10-25
US8076336B2 (en) 2011-12-13
AU2009211887B2 (en) 2013-09-19
RU2499797C2 (ru) 2013-11-27
AR070410A1 (es) 2010-04-07
RU2010136957A (ru) 2012-03-20
SI2240487T1 (sl) 2012-04-30
WO2009097970A1 (de) 2009-08-13
MA32061B1 (fr) 2011-02-01
MY152040A (en) 2014-08-15
CN101981034B (zh) 2013-08-14
CA2713550C (en) 2016-06-14
CN101981034A (zh) 2011-02-23
PA8814801A1 (es) 2009-09-17
CY1113228T1 (el) 2016-04-13
CA2713550A1 (en) 2009-08-13
DK2240487T3 (da) 2012-04-02
PE20091455A1 (es) 2009-10-22
JP2011511016A (ja) 2011-04-07
IL207205A0 (en) 2010-12-30
JP5526040B2 (ja) 2014-06-18
US9079906B2 (en) 2015-07-14
AU2009211887A1 (en) 2009-08-13
RS52264B (sr) 2012-10-31
MX2010008490A (es) 2010-08-18
EP2240487B1 (de) 2011-12-14
HK1149011A1 (en) 2011-09-23
PT2240487E (pt) 2012-03-08
US20110034451A1 (en) 2011-02-10
EP2240487A1 (de) 2010-10-20
TW200946532A (en) 2009-11-16
PL2240487T3 (pl) 2012-05-31
NZ587141A (en) 2012-04-27

Similar Documents

Publication Publication Date Title
HRP20130160T1 (hr) Derivati sf5 kao inhibitori par1, njihovo dobivanje, te upotreba kao medikamenata
RU2010136957A (ru) Триазолопиридазины в качестве ингибиторов par1, их получение и применение в качестве лекарственных средств
JP5132673B2 (ja) ヒスタミンｈ４受容体のモジュレーターとしてのインドールおよびベンゾイミダゾール
KR102594441B1 (ko) 플루오르화된 리실 옥시다아제-유사 2 억제제 및 이의 용도
JP2003528810A5 (sr)
RU2008101805A (ru) Новые производные тиофена
RU2006106272A (ru) Бициклические производные имидазола в качестве средства против вирусов семейства flaviviridae
RU2009126739A (ru) Гетероциклические соединения и способы их применения
JP2010505881A5 (sr)
AU2006232871B2 (en) Histamine H3 receptor agents, preparation and therapeutic uses
JP2015526472A5 (sr)
KR20190049584A (ko) 급성 골수성 백혈병 또는 전이성 유방암의 예방 또는 치료용 약제학적 조성물
CA2437718A1 (en) Carboline derivatives
RU2013127155A (ru) Новые замещенные бициклические ароматические соединения в качестве ингибиторов s-нитрозоглутатион-редуктазы
EA017737B1 (ru) Азотсодержащие бициклические соединения, активные при состояниях хронической боли
JP2013535414A5 (sr)
HUT61533A (en) Process for producing 6,7-dihydro-3-phenyl-1,2-benzisoxazole-4(5h)-one and -ol derivatives and pharmaceutical compositions comprising such derivatives as active ingredient
JP5577259B2 (ja) Ｐａｒ１阻害剤としてのトリアゾリウム塩、その製造、及び薬剤としての使用
JP2024507222A (ja) 第ＸＩＩａ因子阻害剤
JP2012505226A5 (sr)
CN101980710A (zh) 作为par1抑制剂的咪唑并哒嗪、其制备及其作为药物的用途
RU2012110397A (ru) Диземещенные [4-(5-аминометил-фенил)-пиперидин-1-ил]-1н-индол-3-ил]-метаноны
JP2007518781A5 (sr)
ZA200608875B (en) Prolinyl derivatives for treating thrombosis
PL183618B1 (pl) Nowy związek, pochodna podstawionej tetracyklicznej oksazepiny lub tiazepiny, kompozycja farmaceutyczna i sposób wytwarzania pochodnej podstawionej tetracyklicznej oksazepiny lub tiazepiny